Clinical Features

The Treatment Potential of Innate lymphocytes for HIV infection

The current COVID-19 pandemic has shifted attention away from the HIV pandemic which has been ongoing for 40 years and lost 36 million lives

HIV

The Treatment Potential of Innate lymphocytes for HIV infection

The current COVID-19 pandemic has shifted attention away from the human immunodeficiency virus (HIV) pandemic which has been ongoing for 40 years and has claimed over 36 million lives. And it is not over – currently there are more than 37 million people living with HIV. Until the mid-1990s, a positive HIV test meant almost certain progression to death within 10-15 years, but now with antiretroviral therapy (ART), HIV-positive people can live relatively normal healthy lives. Over 60% of people with HIV live in sub-Saharan Africa, and equitable access to ART in these regions took many years. But now over 27 million people worldwide are on ART for HIV – about 73% of the people who need it. With 1.5 million new infections every year and the majority being treated, the number of people living with HIV is increasing year on year.

For verified healthcare professionals

Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.

Register for free Log in

Join the conversation

Comments are open to registered members. Log in or register to share your thoughts on this article.

Log in to comment Register for free